



**Santhera Pharmaceuticals Holding AG**

Hammerstrasse 49

CH-4410 Liestal / Switzerland

Phone +41 61 906 89 50

Fax +41 61 906 89 51

[www.santhera.com](http://www.santhera.com)

## **Santhera Appoints Chief Financial Officer**

**Liestal, Switzerland, June 22, 2015 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Christoph Rentsch as Chief Financial Officer.**

With effect from July 1, 2015, the Santhera Board of Directors appoints **Christoph Rentsch** as CFO and member of the Executive Management Team headed by Chief Executive Officer Thomas Meier, PhD.

Christoph Rentsch started his career in investment banking at Credit Suisse. Subsequently, he worked for Lonza both in Switzerland and the US. Thereafter he joined Roche as Head of Group Funding and Capital Markets for several years before he became partner of Caperis Ltd, an investment advisory and management firm. Since 2010 he served as CFO of privately-held Polyphor, where he led several financing rounds and supported the company in key stages of its development. Christoph Rentsch holds a degree in economics and business administration from the University of Applied Sciences, Basel.

"Christoph Rentsch brings extensive financial, strategic, and operational expertise to Santhera that will further strengthen the management team," said **Martin Gertsch**, Chairman of the Santhera Board of Directors. "His appointment reflects the growth potential we foresee for Santhera. We are delighted he will be part of the leadership team as we move forward."

"This is an exciting time for Santhera," added **Christoph Rentsch**. "As the company transitions from a development-stage to a product company, I am looking forward to working with the Executive Management Team and contributing to a successful implementation of the company's growth strategy."

"I am very pleased to welcome Christoph to the Executive Management Team," commented **Thomas Meier**, PhD, CEO of Santhera. "With his background in the biotech/pharma sector, he will contribute the financial expertise which we need now to implement our commercial operations plans and to build the product pipeline in the future."

Further information on Santhera's Executive Management is available on the Company's website.

### **About Santhera**

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera develops Raxone<sup>®</sup>/Catena<sup>®</sup> as treatment for patients with Leber's Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy (DMD) and primary progressive Multiple Sclerosis (ppMS) and omigapil for Congenital Muscular

Dystrophies (CMD), all areas of high unmet medical need for which no therapies are currently available. For further information, please visit the Company's website [www.santhera.com](http://www.santhera.com).

*Raxone<sup>®</sup> and Catena<sup>®</sup> are trademarks of Santhera Pharmaceuticals.*

**For further information, contact:**

Thomas Meier, PhD, Chief Executive Officer  
Phone +41 61 906 89 64  
[thomas.meier@santhera.com](mailto:thomas.meier@santhera.com)

**US investor contact:**

Andrew McDonald, LifeSci Advisors, LLC  
Phone +1 646 597 6979  
[andrew@lifesciadvisors.com](mailto:andrew@lifesciadvisors.com)

**US Public Relations contact:**

Deanne Eagle, Planet Communications  
Phone +1 917 837 5866  
[deanne@planetcommunications.nyc](mailto:deanne@planetcommunications.nyc)

**Disclaimer / Forward-looking statements**

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

###